Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

PURPOSE: Targeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients with PAH have a deficiency of prostacyclin and prostacyclin synthase. Selexipag is an orally available and selective prostacyclin receptor (IP receptor) agonist. Selexipag...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufmann, Priska, Okubo, Kaori, Bruderer, Shirin, Mant, Tim, Yamada, Tetsuhiro, Dingemanse, Jasper, Mukai, Hideya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452035/
https://www.ncbi.nlm.nih.gov/pubmed/25850750
http://dx.doi.org/10.1007/s40256-015-0117-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452035/
https://www.ncbi.nlm.nih.gov/pubmed/25850750
http://dx.doi.org/10.1007/s40256-015-0117-4

Ejemplares similares